| Ytd | -34.79% | |
| 1y | -34.50% |
| Open | 84.79 | Prev Close | 86.33 | Low | 81.19 | High | 85.31 | Mkt Cap | 2.53B |
| Vol | 504.19K | Avg Vol | 860.74K | EPS | -3.57 | P/E | N/A | Forward P/E | 72.56 |
| Beta | 1.98 | Short Ratio | 7.50 | Inst. Own | 107.61% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-27 | 50-d Avg | 70.55 | 200-d Avg | 85.99 | 1yr Est | 90.44 |
WGS News
On August 26, 2026, GeneDx Holdings Corp (WGS) shares rose 3.3%, bringing the current price to $90.2
Bears have piled into a familiar batch of volatile, heavily bet-against names, and nowhere is the wa
Ondas, SoundHound AI and CleanSpark are in the top ten most-heavily shorted stocks in the market rig
[url="]GeneDx[/url] (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through
Published in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequen
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Seattle Children's show hospital-wide rapid genome se
GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near
GeneDx shows early signs of operational recovery, with Q2 revenue and margins exceeding expectations
On August 11, 2026, GeneDx Holdings Corp (WGS) shares rose 5.1% to $81.83, bouncing back in a volati
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx launches a new online offering to expand access to exome
Dimensional Fund Advisors LP boosted its position in GeneDx Holdings Corp. (NASDAQ: WGS) by 143.4% d
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced that company management will part
Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raise
GeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call Transcript
GeneDx NASDAQ: WGS reported second-quarter revenue of $114.4 million, above its prior guidance, as e
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.01 per share, beating the Zacks C
GeneDx Hldgs (NASDAQ:WGS) reported quarterly earnings of $0.01 per share which beat the analyst cons
GeneDx Holdings (NASDAQ:WGS) affirms FY2026 sales outlook from $475.000 million-$490.000 million to
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today reported its financial and operationa
New York, New York--(Newsfile Corp. - August 3, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nation
[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potent
NEW YORK--(BUSINESS WIRE)---- $WGS #ClassAction--Faruqi & Faruqi, LLP, a leading national securities
LOS ANGELES, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shar
LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action laws
LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- Schall Brown & Schwartz LLP, a national shareholder rights
Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the p
Piper Sandler analyst David Westenberg maintains GeneDx Holdings (NASDAQ:WGS) with a Overweight a
GeneDx (WGS) shares rebound 12% as bargain hunters move in following a steep post-earnings sell-off.
Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lower
US stocks rise, Nasdaq gains 1%. Dow up 0.57%, Nasdaq up 1.03%, S&P 500 up 0.84%. Materials up 2
US stocks rise, Dow gains 300 points. Materials jump 1.8%, real estate falls 0.2%. Pfizer's Q1 e
Wells Fargo analyst Brandon Couillard maintains GeneDx Holdings (NASDAQ:WGS) with a Overweight an
Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lowers the p
Dow futures up 100 pts. Shares of GeneDx Holdings (WGS) down 39.2% after cutting FY26 sales guidance
BTIG analyst Mark Massaro maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lowers the price
Shares of Sterling Infrastructure Inc (NASDAQ: STRL) jumped 22.5% in pre-market trading after report
GeneDx Hldgs (NASDAQ:WGS) reported quarterly losses of $(0.28) per share which missed the analyst co
GeneDx Holdings (NASDAQ:WGS) lowers FY2026 sales outlook from $540.000 million-$555.000 million to $
Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lowers the p
Cathie Wood and Ark Invest have been snatching up shares of a small cap diagnostics company for seve
Zevra Therapeutics jumped in Tuesday premarket trading after partnering with GeneDx to expand NPC ge
Piper Sandler analyst David Westenberg maintains GeneDx Holdings (NASDAQ:WGS) with a Overweight a
BTIG analyst Mark Massaro maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lowers the price